Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Change in Account Payables (2019 - 2025)

Historic Change in Account Payables for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to -$1.1 million.

  • Allogene Therapeutics' Change in Account Payables rose 8516.67% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.8 million, marking a year-over-year decrease of 11406.44%. This contributed to the annual value of -$503000.0 for FY2024, which is 9329.51% up from last year.
  • As of Q3 2025, Allogene Therapeutics' Change in Account Payables stood at -$1.1 million, which was up 8516.67% from -$422000.0 recorded in Q2 2025.
  • Allogene Therapeutics' 5-year Change in Account Payables high stood at $6.8 million for Q2 2024, and its period low was -$7.2 million during Q3 2024.
  • For the 5-year period, Allogene Therapeutics' Change in Account Payables averaged around -$301789.5, with its median value being -$302000.0 (2023).
  • Over the last 5 years, Allogene Therapeutics' Change in Account Payables had its largest YoY gain of 49770.11% in 2021, and its largest YoY loss of 66635.86% in 2021.
  • Quarter analysis of 5 years shows Allogene Therapeutics' Change in Account Payables stood at -$2.0 million in 2021, then skyrocketed by 243.74% to $2.9 million in 2022, then tumbled by 110.28% to -$302000.0 in 2023, then surged by 111.26% to $34000.0 in 2024, then plummeted by 3252.94% to -$1.1 million in 2025.
  • Its Change in Account Payables stands at -$1.1 million for Q3 2025, versus -$422000.0 for Q2 2025 and -$336000.0 for Q1 2025.